Objective:This randomized,double-blind,zopiclone-controlled,multi-center clinical trial assessed the efficacy and safety of eszopiclone in treating patients with primary insomnia.Methods:A total of 225 outpatients with primary insomnia were randomized to receive either eszopiclone 3 mg(n=113) or zopiclone 7.5 mg(n=112) at bedtime for 2 weeks.The diagnosis of primary insomnia was made according to the Chinese Classification and Diagnostic Criteria for Mental Disorders,the 3rd edition(CCMD-3) criteria.Efficacy was evaluated with score changes of the Sleep Dysfunction Rating Scale(SDRS) and Clinical Global Impression(CGI),and safety with physical examination,laboratory tests,electrocardiography and side effects report.Results:Patients treated with eszopiclone had similar reduction rate of SDRS score(60.0%) to ones with zopiclone(62.5%).Treatment was well tolerated by patients,and the most common treatment-related adverse event was unpleasant taste.Conclusion:Eszopiclone is effective in treatment of primary insomnia with well toleronce.